Meeting NewsVideo

VIDEO: Women with osteoporosis had reduction in vertebral, nonvertebral fractures with abaloparatide, alendronate

SAN DIEGO — At the American College of Rheumatology Annual Meeting, Robin K. Dore, MD, spoke about results of the ACTIVExtend trial of postmenopausal women with osteoporosis. She said results showed that women who received abaloparatide for 18 months followed by 24 months of alendronate had a sustained decrease of vertebral and nonvertebral fractures compared to women who received placebo followed by alendronate.

SAN DIEGO — At the American College of Rheumatology Annual Meeting, Robin K. Dore, MD, spoke about results of the ACTIVExtend trial of postmenopausal women with osteoporosis. She said results showed that women who received abaloparatide for 18 months followed by 24 months of alendronate had a sustained decrease of vertebral and nonvertebral fractures compared to women who received placebo followed by alendronate.

    See more from American College of Rheumatology Annual Meeting